Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Feb;69(2):286–290. doi: 10.1038/bjc.1994.53

Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.

A S Adamson 1, P Luckert 1, M Pollard 1, M E Snell 1, M Amirkhosravi 1, J L Francis 1
PMCID: PMC1968672  PMID: 8297726

Abstract

Using a one-stage kinetic chromogenic assay, we studied the procoagulant activity (PCA) of prostatic tissue in an experimental model of prostate cancer in the rat. PCA was present in homogenates of rat prostate glands containing either benign or malignant tumours. The procoagulant activated factor X directly and was provisionally characterised as a tissue factor-factor VIIa complex. There was no significant differences in PCA between control rats and rats exposed to carcinogens that did not develop tumour. Levels in rats that developed tumours were significantly higher (P < 0.01) than all other groups and there was a positive correlation between tumour weight and PCA (r = 0.85, P < 0.001). Furthermore, prostatic PCA levels were higher in the metastasis (P < 0.02). We conclude that PCA reflects the malignant phenotype in this animals, the PCA of the primary tumour was compared with that of the corresponding secondary deposit and levels were higher in the metastasis (P < 0.02). We conclude that PCA reflects the malignant phenotype in this model of experimental prostate cancer and suggest that this parameter is worth evaluating as a potential tumour marker in the human disease.

Full text

PDF
286

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adamson A. S., Francis J. L., Witherow R. O., Snell M. E. Coagulopathy in the prostate cancer patient: prevalence and clinical relevance. Ann R Coll Surg Engl. 1993 Mar;75(2):100–104. [PMC free article] [PubMed] [Google Scholar]
  2. Badenoch-Jones P., Ramshaw I. A. Characterisation of rat tumour cell hybrids: procoagulant and fibrinolytic activities. Aust J Exp Biol Med Sci. 1985 Feb;63(Pt 1):91–98. doi: 10.1038/icb.1985.11. [DOI] [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  4. Brozna J. P. Cellular regulation of tissue factor. Blood Coagul Fibrinolysis. 1990 Oct;1(4-5):415–426. doi: 10.1097/00001721-199010000-00009. [DOI] [PubMed] [Google Scholar]
  5. Carty N., Taylor I., Roath O. S., el-Baruni K., Francis J. L. Urinary tissue factor activity in malignancy. Thromb Res. 1990 Feb 1;57(3):473–478. doi: 10.1016/0049-3848(90)90263-c. [DOI] [PubMed] [Google Scholar]
  6. Donati M. B., Gambacorti-Passerini C., Casali B., Falanga A., Vannotti P., Fossati G., Semeraro N., Gordon S. G. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res. 1986 Dec;46(12 Pt 1):6471–6474. [PubMed] [Google Scholar]
  7. Edwards R. L., Morgan D. L., Rickles F. R. Animal tumor procoagulants: registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis. Thromb Haemost. 1990 Feb 19;63(1):133–138. [PubMed] [Google Scholar]
  8. Edwards R. L., Rickles F. R., Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J Lab Clin Med. 1981 Dec;98(6):917–928. [PubMed] [Google Scholar]
  9. Edwards R. L., Silver J., Rickles F. R. Human tumor procoagulants: registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis. Thromb Haemost. 1993 Feb 1;69(2):205–213. [PubMed] [Google Scholar]
  10. Francis J. L. Haemostasis and cancer. Med Lab Sci. 1989 Oct;46(4):331–346. [PubMed] [Google Scholar]
  11. Francis J. L., el-Baruni K., Roath O. S., Taylor I. Factor X-activating activity in normal and malignant colorectal tissue. Thromb Res. 1988 Nov 1;52(3):207–217. doi: 10.1016/0049-3848(88)90080-1. [DOI] [PubMed] [Google Scholar]
  12. Gasic G. J. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev. 1984;3(2):99–114. doi: 10.1007/BF00047657. [DOI] [PubMed] [Google Scholar]
  13. Gilbert L. C., Gordon S. G. Relationship between cellular procoagulant activity and metastatic capacity of B16 mouse melanoma variants. Cancer Res. 1983 Feb;43(2):536–540. [PubMed] [Google Scholar]
  14. Gordon S. G., Cross B. A. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. Cancer Res. 1990 Oct 1;50(19):6229–6234. [PubMed] [Google Scholar]
  15. Gordon S. G., Franks J. J., Lewis B. J. Comparison of procoagulant activities in extracts of normal and malignant human tissue. J Natl Cancer Inst. 1979 Apr;62(4):773–776. [PubMed] [Google Scholar]
  16. Gordon S. G., Franks J. J., Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res. 1975 Feb;6(2):127–137. doi: 10.1016/0049-3848(75)90018-3. [DOI] [PubMed] [Google Scholar]
  17. Johansson J. E., Adami H. O., Andersson S. O., Bergström R., Krusemo U. B., Kraaz W. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet. 1989 Apr 15;1(8642):799–803. doi: 10.1016/s0140-6736(89)92269-1. [DOI] [PubMed] [Google Scholar]
  18. Kadish J. L., Wenc K. M., Dvorak H. F. Tissue factor activity of normal and neoplastic cells: quantitation and species specificity. J Natl Cancer Inst. 1983 Mar;70(3):551–557. [PubMed] [Google Scholar]
  19. Liotta L. A., Saidel M. G., Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res. 1976 Mar;36(3):889–894. [PubMed] [Google Scholar]
  20. Mussoni L., Conforti G., Gambacorti-Passerini C., Alessio G., Pepe S., Vaghi M., Erba E., Amato G., Landoni F., Mangioni C. Procoagulant and fibrinolytic activity of human ovarian carcinoma cells in culture. Eur J Cancer Clin Oncol. 1986 Apr;22(4):373–380. doi: 10.1016/0277-5379(86)90101-x. [DOI] [PubMed] [Google Scholar]
  21. Nakao J., Change W. C., Murota S. I., Orimo H. Testosterone inhibits prostacyclin production by rat aortic smooth muscle cells in culture. Atherosclerosis. 1981 May;39(2):203–209. doi: 10.1016/0021-9150(81)90070-8. [DOI] [PubMed] [Google Scholar]
  22. Neubauer B. L., Bemis K. G., Best K. L., Goode R. L., Hoover D. M., Smith G. F., Tanzer L. R., Merriman R. L. Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat. J Urol. 1986 Jan;135(1):163–166. doi: 10.1016/s0022-5347(17)45554-6. [DOI] [PubMed] [Google Scholar]
  23. O'MEARA R. A. Coagulative properties of cancers. Ir J Med Sci. 1958 Oct;394:474–479. [PubMed] [Google Scholar]
  24. Pangasnan R. S., Devereux D., DeCunzo L. P., Karp G. I. The production of a factor X activator by a methylcholanthrene-induced rat fibrosarcoma. Thromb Haemost. 1992 Oct 5;68(4):407–412. [PubMed] [Google Scholar]
  25. Pollard M., Luckert P. H. Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone. J Natl Cancer Inst. 1986 Aug;77(2):583–587. [PubMed] [Google Scholar]
  26. Pollard M., Luckert P. H. Transplantable metastasizing prostate adenocarcinomas in rats. J Natl Cancer Inst. 1975 Mar;54(3):643–649. [PubMed] [Google Scholar]
  27. Pusey M. L., Mende T. J. Studies on the procoagulant activity of human amniotic fluid. II. The role of factor VII. Thromb Res. 1985 Sep 1;39(5):571–585. doi: 10.1016/0049-3848(85)90237-3. [DOI] [PubMed] [Google Scholar]
  28. Sack G. H., Jr, Levin J., Bell W. R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977 Jan;56(1):1–37. [PubMed] [Google Scholar]
  29. Szczepański M., Bardadin K., Zawadzki J., Pypno W. Procoagulant activity of gastric, colorectal, and renal cancer is factor VII-dependent. J Cancer Res Clin Oncol. 1988;114(5):519–522. doi: 10.1007/BF00391504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Weiss H. J. Platelet physiology and abnormalities of platelet function (first of two parts). N Engl J Med. 1975 Sep 11;293(11):531–541. doi: 10.1056/NEJM197509112931105. [DOI] [PubMed] [Google Scholar]
  31. Whitmore W. F., Jr Natural history of low-stage prostatic cancer and the impact of early detection. Urol Clin North Am. 1990 Nov;17(4):689–697. [PubMed] [Google Scholar]
  32. Wijngaards G., Immerzeel J. Divalent cations and complex formation between tissue thromboplastin and factor VII. Biochem Biophys Res Commun. 1977 Jul 25;77(2):658–664. doi: 10.1016/s0006-291x(77)80029-6. [DOI] [PubMed] [Google Scholar]
  33. Zacharski L. R., Memoli V. A., Rousseau S. M. Coagulation-cancer interaction in situ in renal cell carcinoma. Blood. 1986 Aug;68(2):394–399. [PubMed] [Google Scholar]
  34. el-Baruni K., Taylor I., Roath S., Francis J. L. Factor X-activating procoagulant in normal and malignant breast tissue. Hematol Oncol. 1990 Nov-Dec;8(6):323–332. doi: 10.1002/hon.2900080604. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES